GenCell 2025: The Old Revenue Base Collapsed, and the New Thesis Sits on One Charging Site

Getting to Know the Company

The easy mistake with GenCell is to read this report as if it describes one continuous company. In practice it describes two different layers. The 2025 statements still show a hydrogen and fuel-cell company whose revenue base collapsed, whose organization was cut to the bone, and whose gross economics worsened sharply. But the strategic narrative around the report already points somewhere else: a much leaner company, a new controlling shareholder, one charging asset at the Dead Sea, and a hope that this asset can become the base for a new cash-generating model. If you read only the numbers, you miss the pivot. If you read only the pivot, you miss how thin the remaining operating base really is.

What is actually working now? The cost reset is real. Cash burn from operating activity fell to $8.999 million from $18.264 million in 2024. R&D expense dropped to $4.442 million from $8.314 million. The European telecom receivable was collected after year-end. Barclays financing also bought time, with the first loan payment pushed out to June 30, 2027.

What is still not clean? Revenue fell to just $1.906 million, down 80% year over year. The $4.589 million Mexico customer balance was fully provided for. Gross loss widened to $6.238 million. And while the company now talks about a revenue-generating charging asset, the audited 2025 statements still do not reflect the change-of-control equity issue, the charging-station acquisition, or the controlling-shareholder loan tied to the transaction. The company explicitly says those layers will be reflected in the 2026 statements.

This matters now for another reason: actionability. Based on the latest trading snapshot from April 6, 2026, the stock traded at 119.9 agorot on just ILS 2,598 of daily turnover. Even if one derives a market cap of roughly ILS 54 million from the last price and share count, this is still a stock with a real liquidity constraint.

So what has to happen for the read to improve? The Dead Sea charging site has to open commercially on time, show usage rather than just physical existence, the revenue base has to widen beyond one European telecom customer, and the company has to prove that a 10-person organization can support both the legacy customer base and the new asset-led model. Until that happens, 2026 looks like a bridge year with a proof test, not a breakout year.

Four Things That Matter More Than the Headline

• The strategy changed faster than the balance sheet. The annual narrative is already about charging assets, control change, and shareholder financing, while the December 31, 2025 balance sheet still mostly reflects the old company.
• The reported operating improvement did not come from the operating core. Ordinary operating loss actually increased to $19.879 million from $19.198 million in 2024. The lower post-impairment operating loss mainly came from a $5.347 million reversal of prior impairments.
• The credit problem did not disappear, it changed shape. Mexico became a full write-off issue, while 2025 leaned heavily on one European telecom customer.
• This is no longer a broad development platform. Headcount fell from 105 at the end of 2024 to 15 at the end of 2025 and 10 near the report date, with zero manufacturing employees and zero R&D employees by the report date.

The Business Map Today

This chart makes the shift visible immediately: 2024 was effectively a Mexico year, 2025 became a Swiss and European telecom year, and the Israeli activity that now anchors the strategic story still does not contribute materially to the revenue line in this report.

This is the scale of the pivot. End-2025 GenCell is no longer a fuel-cell development and manufacturing company in the old sense. It is a much smaller organization built around integration, service, energy management, and an attempt to commercialize one charging asset.

Events and Triggers

The first trigger: In January and March 2025 the company updated its strategy. The decisions were blunt: outsource EVOX completely, stop producing the alkaline fuel cells developed in-house, reduce investment in non-core projects such as green ammonia and ACU, and look for financing alternatives, strategic partners, mergers, or asset sales. This is not the language of broad platform expansion. It is the language of focused survival.

The second trigger: The Barclays deal, signed in August 2025, changed control. Barclays received 23,183,947 shares for ILS 30 million, taking 51% of the company, and also received a PUT structure around two energy assets. In November 2025 the charging-site PUT was exercised. The valuation attached ILS 75.679 million plus VAT to the charging asset, and after offsetting the equity consideration, Barclays extended a loan of ILS 59.3 million, including VAT.

The third trigger: On March 30, 2026, the first Barclays loan payment was deferred to June 30, 2027 instead of June 30, 2026. According to the note, that first payment is set at ILS 3 million. All other loan terms remained in place, including prime plus 0.5% interest and the charge over the station. This is a meaningful financing event. It does not solve the business question, but it clearly eases near-term pressure.

The fourth trigger: The company completed the Dead Sea charging site and entered the EV charging activity from January 2026, but the site was still not open to the public as of the report date. The company says it is still upgrading the site's design, visibility, and ancillary services, and expects a full commercial opening in the second quarter of 2026. In other words, the new thesis now has a real asset, but it still lacks a usage proof point.

The fifth trigger: After year-end the company further reduced its U.S. activity, canceled the UCLA arrangement by mutual agreement with no penalties, and made clear that it is looking for a partner or investor for the U.S.-adapted EVOX technology. That closes another door on the older narrative of standalone U.S. commercialization.

The sixth trigger: On January 19, 2026, GenCell received a notice from Barclays to examine the possible transfer of additional energy-producing assets, and later also the possibility of a share-exchange tender offer. The company is explicit that there is no certainty around execution, timing, scale, or terms. This is an important distinction: an interesting strategic thread, but not yet a hard economic fact.

The backlog is small, but also very telling: $2.16 million, entirely in the first half of 2026. So the real question is not whether 2026 can start reasonably. The question is what remains after the first half.

Efficiency, Profitability, and Competition

The key point here is that GenCell cut costs faster than many readers may expect, but it did not make the operating core economically healthier. Revenue fell from $9.549 million in 2024 to $1.906 million in 2025. Cost of sales fell only from $10.496 million to $8.144 million. The result was a gross loss of $6.238 million, versus just $947 thousand in 2024.

The chart makes the structure clear. 2024 was a high-revenue year, but not necessarily a healthier one. In 2025 the revenue base became far narrower, so even after aggressive cuts the ordinary operating business remained deeply loss-making.

The biggest cuts came from R&D and sales and marketing. R&D fell 46.6% to $4.442 million. Sales and marketing fell 58.1% to $1.6 million. But G&A rose to $7.599 million from $6.116 million, mainly because of a $4.213 million expected-credit-loss charge and a $368 thousand restructuring provision, which more than offset lower payroll and lower office costs.

There is also an accounting nuance here that matters a lot. Ordinary operating loss, before impairment items, actually worsened slightly. What improved the later operating line was a $5.347 million reversal of prior impairment, offset partly by a $4.642 million loss on disposals and abandonment of fixed assets and right-of-use assets. These are not the same quality of earnings. A reader who looks only at the post-impairment operating line could walk away thinking the core business improved. That would be wrong.

Commercially, 2025 was almost entirely a BOX year. According to the product split, BOX contributed $1.731 million, or 91% of revenue, while REX contributed only $175 thousand. In 2024 the picture had been nearly the reverse.

At the customer level the revenue base is equally narrow. The leading customer in 2025 was a major European telecom company, contributing $1.674 million, or 88% of revenue. GenCell Mexico contributed just $175 thousand, or 9%. The rest barely matters.

That matters because the quality of the revenue story is not just about the top line. It is about the customer and the cash. In the European telecom case, the company says it delivered 35 systems and installed 7 during 2025, recognized $1.674 million of revenue, collected $1.054 million by year-end, and collected the remainder by the approval date of the statements. That is a positive sign. In Mexico, the story is the opposite: the loan to the partner was repaid, but the commercial receivable ended in a full provision.

Competition adds another layer. The company itself says that in fast charging, advantage no longer depends only on hardware. It depends on location, financing, service, energy management, and site quality. This is precisely where GenCell still has more to prove. One charging site that is not yet open to the public is not a platform. Even in the hydrogen-side product lines, the company now admits that FOX is still not a commercial product, the Deutsche Telekom relationship never turned into binding commercial orders, and the Linde agreement has expired. So the problem is not only competition. It is also a commercialization track record that remains thin.

Cash Flow, Debt, and Capital Structure

This is best framed through all-in cash flexibility. Not through normalized cash generation, but through the question of how much cash really remains after actual cash uses. At the end of 2025, even after the cost reset, even after deposits were released, and even before the charging station and Barclays loan enter the balance sheet, the answer is still: not much room.

Cash and cash equivalents fell to $2.869 million from $12.326 million at the end of 2024. If one adds restricted deposits of $621 thousand and short-term deposits of $1.351 million, the company gets to roughly $4.8 million of gross liquidity, which is also the framing management uses when discussing runway. Working capital remained positive at $3.566 million, but it is no longer generous.

The important point in this chart is that the improvement in cash burn did not come from a business breakout. It came mainly from working-capital release and lower costs. In the operating cash flow appendix, one sees a $2.373 million decrease in receivables, a $2.120 million decrease in other receivables, and a $1.367 million decrease in inventory. In other words, 2025 was also a balance-sheet contraction year, not only a commercialization year.

Management's own runway assumptions also deserve attention. The company says it has 15 to 18 months of funding from the approval date of the financial statements, but that depends on several conditions: no new inventory build or fixed-asset purchases, collection of the existing orders, a favorable outcome in the EV Motors counterclaim, Barclays loan repayment starting only in June 2027, and only about ILS 1 million of additional investment for site design and ancillary services at the charging station. That buys time, but it also shows how limited the margin for error still is.

Another important yellow flag is the auditors' emphasis-of-matter paragraph. There is no modified opinion, but there is a clear callout around business condition: uncertainty regarding demand, market penetration, dependence on one revenue-generating asset, technological and regulatory change, competition, the ability to raise fresh capital, and the timing of collections from customers. Put simply, the auditors are not saying the company cannot continue. They are saying continued operation still depends on assumptions that have not yet been fully proven.

The New Debt Layer Sits Outside the 2025 Balance Sheet

This is one of the most important points in the whole report. The charging site and the Barclays loan are the heart of the new story, but in Note 1 the company says it will reflect the equity issue, the charging-site acquisition, and the Barclays loan in the 2026 financial statements. So anyone trying to infer the new capital structure from the December 31, 2025 balance sheet is reading the wrong year.

So two pictures need to be held at once. The first is the audited year-end 2025 balance sheet, which still describes a small company with limited capital cushion. The second is the 2026 layer, where the controlling shareholder finances the new asset and the company will have to prove that the asset can support the financing, not merely justify a headline valuation.

Forecasts and Outlook

Four points will determine how 2026 is read before any headline does:

1. The 2026 revenue runway starts short. Backlog is just $2.16 million, all in the first half.
2. The European customer matters, but it is not diversification. Post-year-end collection improves revenue quality, not breadth.
3. The charging site has not yet proven usage. It exists, but the new revenue thesis will only be tested after public opening.
4. The next phase is still funded mainly by the controlling shareholder. The financing relief is real, but it is not the same thing as self-generated operating cash.

In that sense, 2026 looks like a commercial proof year, not a breakout year. The company expects to open the Dead Sea charging site to the public in the second quarter of 2026. It also says it wants to build several large charging sites in Israel and become a leading player in tourism-heavy and endpoint locations in the north and south. But there is still a gap between strategic intent and economics: as of the report date, the company has one asset, and that asset is not yet open to the public.

The company itself is fairly clear on what makes the charging model harder than the headline suggests. It explicitly lists dependence on the power grid, sensitivity to Israeli electricity prices, financing needs, high upfront CAPEX, long-term agreements, and exit costs. This is infrastructure language, not software language. So even if the site opens on time, the market will not focus only on the opening date. It will focus on utilization, tariffs, load management, and margin.

What supports the outlook? Two things mainly. First, a large part of the older collection problem has already been pushed into conservative accounting. GenCell Mexico is fully reserved, while the European telecom balance was collected after year-end. Second, the Barclays loan was deferred by a year, so the company does not have to start servicing it in June 2026. That matters precisely in the window when the charging asset is supposed to begin proving itself.

What weighs on the story? The historical revenue base remains extremely narrow. The company says the current backlog mainly comes from the European telecom transaction, and that the gap versus prior backlog expectations reflects delays in installations and regulatory approvals. It also states clearly that backlog is not really relevant in the charging segment, because that activity is based on real-time end-customer sales. So 2026 cannot be read through backlog alone. It has to be read through traffic and station economics.

There is also another strategic layer. In January 2026 Barclays raised the possibility of transferring additional energy assets into the company. If that happens, the thesis could move quickly from a one-asset read to a platform-asset read. But as of the report date, the company itself emphasizes that there is no certainty around execution, timing, scale, or terms. That should not be turned into a stronger fact than the evidence supports.

What must happen over the next 2 to 4 quarters for the thesis to hold? First, full commercial opening of the Dead Sea charging site and the start of real usage. Second, full delivery of the $2.16 million backlog without further slippage. Third, a new demand layer beyond the European telecom customer. Fourth, liquidity that lets the company operate without another urgent financing move. If those four things do not happen, the pivot will remain more structural than economic.

Risks

Revenue Concentration and Credit

The first risk is obvious: the revenue base is very narrow. In 2025 the European telecom customer represented 88% of revenue, and GenCell Mexico another 9%. That means the company did not just lose revenue breadth. It lost diversification. At the same time, the Mexico receivable stood at $4.589 million at year-end and was fully reserved. That was the right accounting move, but it is also proof that the older commercialization story did not end well.

The EV Motors layer is still unresolved too. As of the report date, the customer balance stood at $3.638 million, and the company says that even if this amount is not collected it should not damage liquidity because a full expected-credit-loss provision has already been recorded. That limits the direct balance-sheet risk, but not the reputational and management-distraction risk.

Dependence on One Revenue Asset and on Related-Party Financing

This is the core counter-thesis risk. The company is moving toward a revenue-generating asset model, but right now it has only one charging asset. Any opening delay, cost overrun, connection issue, or electricity-price squeeze hits the new layer directly. At the same time, the site is pledged to Barclays and the main financing for the new model comes from the controlling shareholder. That gives the company support, but it also creates dependence.

Execution Risk Inside a Very Lean Organization

A 10-person organization can be efficient, but it also leaves little room for execution misses. At GenCell this is especially visible because the company still has to support existing customers, maintain already installed systems, operate a new charging site, pursue new partnerships, and keep looking for a broader revenue base. There is not much slack in that setup.

Liquidity, Dilution, and Trading Friction

Even after the Barclays deal, the company says it may raise more financing as needed. It also approved a structure under which the entire Barclays loan would convert into equity if the company raises public or institutional capital equal to or above the loan amount within 12 months from the January 2026 approval. So the dilution layer is not closed. On top of that, trading liquidity is extremely low, which makes the market response to the story less stable and less efficient.

The short-interest layer is less central here. In the last available short snapshot, from May 8, 2025, short float had fallen back to 0.00% after peaking at 5.04% on April 10, 2025. That retreat is notable, but it is hard to read too much into it when the stock trades on such thin volume. The more important signal right now is liquidity, not short positioning.

Conclusions

End-2025 GenCell is no longer a hydrogen-development company trying to be everything at once. It is a much leaner organization, with a heavily reduced revenue base, a full reserve against the Mexico customer, and an attempt to rebuild the economic story around one charging asset and controlling-shareholder financing. What supports the thesis today is that the cuts were real, the European telecom receivable was collected after year-end, and Barclays bought the company both time and a clearer direction. The main block is that the new direction still has not proven its economics.

Current thesis in one line: GenCell has replaced a broad technology dream with a narrower and more focused structure, but 2026 will decide whether that is a real commercial pivot or simply a time extension around one asset.

What changed versus the older way of reading the company is that the debate no longer centers on new hydrogen products. It now centers on collection quality, the pace of downsizing, and the ability to turn a single charging asset into cash flow. The strongest counter-thesis is that this read may be too conservative: Barclays now controls the company and has incentive to support it, the charging asset is real, the European telecom balance has already been collected, and if even one revenue asset starts performing properly the new base could look more stable than it does today.

What can change the market's interpretation in the short and medium term is not more presentation language but three simple tests: the actual public opening date of the Dead Sea charging site, the first usage pattern after opening, and whether a second revenue layer appears beyond the European telecom contract. That matters because this is where business quality gets tested, not just survival. A company that has survived a deep reset still has to prove it can rebuild a repeatable revenue engine.

Over the next 2 to 4 quarters the thesis improves if the site opens on time and shows usage, if the 2026 backlog is delivered in full, and if a new transaction appears that reduces revenue concentration. It weakens if the opening slips, if the European customer remains almost the whole story, or if the company needs another urgent financing move before the new asset starts working.